Decreased limb muscle and increased abdominal fat linked to higher mortality in people with HIV

Slides from presentation by Rebecca Scherzer.
Liz Highleyman
Published: 02 March 2011

HIV-positive people who lose muscle mass in their arms and legs whilst gaining abdominal fat have a higher likelihood of death, according to findings from the FRAM study presented on Tuesday at the 18th Conference on Retroviruses and Opportunistic Infections (CROI), taking place this week in Boston. But the common measure of body mass index (BMI) may fail to capture this increased risk.

Unintended weight loss and loss of lean muscle due to disease or ageing are known risk factors for mortality. While many studies have looked at body fat changes in people with HIV, less is known about changes in muscle mass.

Rebecca Scherzer from the University of California at San Francisco and colleagues looked at muscle loss, subcutaneous fat loss, and central or abdominal fat gain (reflecting visceral fat around the internal organs) as predictors of death among people with HIV.

The researchers performed whole-body magnetic resonance imaging (MRI) on nearly 1200 HIV-positive participants in the FRAM (Fat Redistribution and Metabolic Change in HIV Infection) study. About two-thirds were men and the average age was just over 40 years. The mean BMI was about 25, the threshold for classification as "overweight".

Looking at all-cause mortality over five years, the investigators found that decreased muscle tissue in the arms and legs, as well as increased belly fat, were strong and consistent predictors of mortality, even after controlling for other risk factors.

After adjusting for demographic factors, cardiovascular risk factors, HIV-related factors including CD4 cell count and viral load, kidney disease, and inflammation markers, people with the lowest arm or leg muscle mass had approximately twice the risk of death, as did those with the most visceral fat.

The researchers calculated that having the lowest level of arm muscle mass could account for 15% of excess mortality in people with HIV, or about two extra deaths over five years. Having the lowest leg mass could account for one additional death.

Contrary to expectations, however, peripheral lipoatrophy, or loss of fat in the arms and legs, was not associated with higher mortality.

"Lower muscle mass and central adiposity appear to be important risk factors for mortality in HIV-infected individuals," the FRAM researchers concluded.

Relying on BMI may underestimate this risk, Scherzer said. BMI, calculated as body weight divided by height squared, is often used as a surrogate measure for body fat. But people who have both excess abdominal fat and reduced limb muscle mass can have a BMI within the normal range.

"BMI is a flawed measure," Scherzer explained at a press conference following the presentation, as it can classify people with a lot of muscle as obese. Instead, she recommended, clinicians should measure waist circumference as a simple indicator of visceral fat, along with mid-arm muscle mass, which can be estimated using mid-arm circumference and triceps skin-fold thickness.

Responding to a question after her presentation, Scherzer said studies of the HIV-negative population find that muscle strength is more important than muscle mass. This offers hope, she said, because it suggests that exercise can lead to improved outcomes.

Reference

Scherzer R et al. Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. 18th Conference on Retroviruses and Opportunistic Infections, Boston, abstract 76, 2011.

Abstract and webcast

You can view the abstracts from this research on the official conference website:

Abstract 76: www.retroconference.org/2011/Abstracts/40032.htm

You can also watch a webcast of the presentations made at this conference session, including the speaker Rebecca Scherzer.

Webcast from HIV complications.

We rely on donations to continue our work to help people with HIV, support us today at: www.aidsmap.com/donate

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.